Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)

Exclusion Criteria

• •Mentally or legally incapacitated
• •History of stroke, chronic seizures, or major neurological disorder
• •History of clinically significant endocrine (except T2DM), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
• •History of neoplastic or myeloproliferative diseases
• •Has clinical unstable or rapidly progressing diabetic retinopathy, neuropathy, and/or frequent nausea, bloating or vomiting, severe gastroesophageal reflux or early satiety
• •Has a history of Type 1 Diabetes and/or history of ketoacidosis
• •Use of any lipid-lowering therapies in the past 3 months
• •Non-permitted medication for a co-morbid condition
• •Excessive alcohol or caffeine use
• •Participation in another investigational study within 4 weeks prior to this study
• •A history of significant multiple and/or severe allergies or anaphylactic reactions
• •Regular user of any illicit drugs or history of alcohol abuse within 6 months